主页文献库搜索
Germline polymorphisms as biomarkers of tumor response in colorectal cancer p...

Morgen(E K),Lenz(H-J),Jonker(D J),Tu(D),Mi... Pharmacogenomics J 0000-00-00

...KRAS (rs61764370) and VEGFA (rs3025039). Meta-analysis yielded nominal significance (at α=0.05) for rs4444903 and rs1154...

Genetic alterations affecting GTPases and T-cell receptor signaling in periph...

Boddicker(Rebecca L),Razidlo(Gina L),Feldm... Small GTPases 0000-00-00

...KRAS and RHOA, respectively. In addition to mutations directly affecting the GTPase pathway, TCR signaling mutations ind...

Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be...

Dou(Yongchao),Cha(Diana J),Franklin(Jeffre... Sci Rep 0000-00-00

...KRAS alleles and isogenically-matched derivative cell lines, DKO-1 (mutant KRAS allele only) and DKs-8 (wild-type KRAS a...

Frequency and distinctive spectrum of KRAS mutations in never smokers with lu...

Riely(G J),Kris(M G),Marks(J L),Li(A),Chit... J Clin Oncol 0000-00-00

...KRAS mutations. The frequency of KRAS mutation was not associated with age, gender, or smoking history. The number of pa...

Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of ...

Jackman(D M),Sequist(L V),Cioffredi(L),Rui... J Clin Oncol 0000-00-00

...KRAS mutations. A total of 121 mutations in EGFR or KRAS were detected. 75 pts had a sensitizing EGFR mutation. (RR = 63...

Phase I trial of combination nab-paclitaxel and pemetrexed in advanced solid ...

Ho(C),Davies(A M),Lara(P N),Chew(H K),Beck... J Clin Oncol 0000-00-00

...KRAS mutations, p16 and APC gene promoter methylation.,Pemetrexed 500 mg/m day 1 with ABI 007 260 mg/m is feasible and w...

Preliminary activity and safety results from a phase I clinical trial of PF-0...

Janne(P A),Schellens(J H),Engelman(J A),Ec... J Clin Oncol 0000-00-00

...KRAS, within the phase I study are reported.,NSCLC pts (n=42) received PF 16 mg (n=1), 30 mg (n=2), 45 mg, the MTD (n=33...

Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment o...

Tzekova(V),Cebotaru(C),Ciuleanu(T E),Damja... J Clin Oncol 0000-00-00

...KRAS gene mutations. MEK1/2 inhibition block the Raf/MEK/ERK pathway since these kinases lie downstream of Ras, and ERK1...

KRAS status and efficacy of first-line treatment of patients with metastatic ...

Bokemeyer(C),Bondarenko(I),Hartmann(J T),D... J Clin Oncol 0000-00-00

...KRAS mutation status.,In general, the population with tissue available for KRAS analysis (n=233) was representative of t...

Relationship of efficacy with KRAS status (wild type versus mutant) in patien...

Tejpar(S),Peeters(M),Humblet(Y),Vermorken(... J Clin Oncol 0000-00-00

...KRAS mutation analysis.,In Arm A, 45 pts were randomized: 19 pts (42%) were KRAS wt, 19 pts (42%) were KRAS mt, and 7 pt...

上一页 931 932 933 934 935 936 937 938 939 下一页 935 / 共 953

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]